Newer IMiDs

Abhishek Singla, Shaji Kumar

Research output: Chapter in Book/Report/Conference proceedingChapter


With the advent of thalidomide, the treatment of multiple myeloma was revolutionized. The drug showed excellent response rates in both previously untreated and relapsed/refractory patients. However, treatment-related toxicities such as somnolence, constipation, and neuropathy were a major limitation to its use. Lenalidomide, a thalidomide analogue, was developed with the hope of improving both the efficacy and toxicity profile of thalidomide and has subsequently shown significant clinical activity in patients with multiple myeloma. Though approved only for relapsed/refractory patients till date, clinical trials using lenalidomide with or without combinations have shown great efficacy in newly diagnosed, as a maintenance therapy and even asymptomatic myeloma. The recent introduction of another thalidomide analogue-pomalidomide has shown significant activity and a great potential for use in relapsed/refractory myeloma including those refractory to lenalidomide and bortezomib.

Original languageEnglish (US)
Title of host publicationTranslational and Clinical Research
PublisherSpringer New York
Number of pages33
ISBN (Electronic)9781461452607
ISBN (Print)1461452597, 9781461452591
StatePublished - May 1 2013

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Newer IMiDs'. Together they form a unique fingerprint.

Cite this